Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE(-/-) mice.
Buday A, Orsy P, Godó M, Mózes M, Kökény G, Lacza Z, Koller A, Ungvári Z, Gross ML, Benyó Z, Hamar P. Buday A, et al. Among authors: orsy p. Am J Physiol Heart Circ Physiol. 2010 Aug;299(2):H386-95. doi: 10.1152/ajpheart.01042.2009. Epub 2010 May 28. Am J Physiol Heart Circ Physiol. 2010. PMID: 20511416 Free PMC article.
NK2 receptor-mediated detrusor muscle contraction involves Gq/11-dependent activation of voltage-dependent Ca2+ channels and the RhoA-Rho kinase pathway.
Dér B, Molnár PJ, Ruisanchez É, Őrsy P, Kerék M, Faragó B, Nyirády P, Offermanns S, Benyó Z. Dér B, et al. Among authors: orsy p. Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1154-F1163. doi: 10.1152/ajprenal.00106.2019. Epub 2019 Aug 28. Am J Physiol Renal Physiol. 2019. PMID: 31461351 Free article.
Intracellular signaling pathways of muscarinic acetylcholine receptor-mediated detrusor muscle contractions.
Balla H, Borsodi K, Őrsy P, Horváth B, Molnár PJ, Lénárt Á, Kosztelnik M, Ruisanchez É, Wess J, Offermanns S, Nyirády P, Benyó Z. Balla H, et al. Among authors: orsy p. Am J Physiol Renal Physiol. 2023 Nov 1;325(5):F618-F628. doi: 10.1152/ajprenal.00261.2022. Epub 2023 Sep 7. Am J Physiol Renal Physiol. 2023. PMID: 37675459 Free article.
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
Sesti G, Bardtrum L, Dagdelen S, Halladin N, Haluzík M, Őrsy P, Rodríguez M, Aroda VR. Sesti G, et al. Among authors: orsy p. Diabetes Obes Metab. 2020 May;22(5):873-878. doi: 10.1111/dom.13957. Epub 2020 Jan 29. Diabetes Obes Metab. 2020. PMID: 31903724 Free PMC article. Clinical Trial.
Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
Janez A, Őrsy P, Stachlewska K, Salvesen-Sykes K, Billings LK, Philis-Tsimikas A. Janez A, et al. Among authors: orsy p. Diabetes Obes Metab. 2020 Apr;22(4):658-668. doi: 10.1111/dom.13944. Epub 2020 Jan 27. Diabetes Obes Metab. 2020. PMID: 31858673 Free PMC article. Clinical Trial.
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L, Doshi A, Gouet D, Vilsbøll T, Begtrup K, Őrsy P, Ranthe MF, Lingvay I. Meneghini L, et al. Among authors: orsy p. Diabet Med. 2020 Feb;37(2):267-276. doi: 10.1111/dme.14178. Epub 2019 Nov 28. Diabet Med. 2020. PMID: 31705547 Free PMC article.
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
Miller E, Doshi A, Grøn R, Jódar E, Őrsy P, Ranthe MF, Sugimoto D, Tentolouris N, Viljoen A, Billings LK. Miller E, et al. Among authors: orsy p. Diabetes Obes Metab. 2019 Dec;21(12):2643-2650. doi: 10.1111/dom.13851. Epub 2019 Aug 28. Diabetes Obes Metab. 2019. PMID: 31385425 Free PMC article. Clinical Trial.
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR, González-Galvez G, Grøn R, Halladin N, Haluzík M, Jermendy G, Kok A, Őrsy P, Sabbah M, Sesti G, Silver R. Aroda VR, et al. Among authors: orsy p. Lancet Diabetes Endocrinol. 2019 Aug;7(8):596-605. doi: 10.1016/S2213-8587(19)30184-6. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189519 Clinical Trial.
11 results